Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H20N2O3.C4H10N2 |
Molecular Weight | 410.5093 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CNCCN1.CCCCC2C(=O)N(N(C2=O)C3=CC=C(O)C=C3)C4=CC=CC=C4
InChI
InChIKey=FHVBBQCPAGHXED-UHFFFAOYSA-N
InChI=1S/C19H20N2O3.C4H10N2/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15;1-2-6-4-3-5-1/h4-8,10-13,17,22H,2-3,9H2,1H3;5-6H,1-4H2
Molecular Formula | C19H20N2O3 |
Molecular Weight | 324.3737 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | C4H10N2 |
Molecular Weight | 86.1356 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Oxyphenbutazone is a non-steroidal anti-inflammatory drug, cyclooxygenase (prostaglandin synthetase) inhibitors which was marked under brand name tandearil for the treatment rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis. But this drug was withdrawn from markets due to bone marrow suppression.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3108222 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | TANDEARIL Approved UseUnknown Launch Date-2.84947186E11 |
|||
Palliative | TANDEARIL Approved UseUnknown Launch Date-2.84947186E11 |
|||
Palliative | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.42 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
97.49 mg single, oral dose: 97.49 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
12 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
94.99 mg single, oral dose: 94.99 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
18.24 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
95.75 mg single, oral dose: 95.75 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
24.05 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
98.82 mg single, oral dose: 98.82 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
24.54 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
95.38 mg single, oral dose: 95.38 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
397.401 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
97.49 mg single, oral dose: 97.49 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
285.932 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
94.99 mg single, oral dose: 94.99 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
381.688 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
95.75 mg single, oral dose: 95.75 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
463.858 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
98.82 mg single, oral dose: 98.82 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
482.606 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
95.38 mg single, oral dose: 95.38 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
800 mg 1 times / day multiple, oral Studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: |
unhealthy, 31-72 years n = 66 Health Status: unhealthy Condition: gout Age Group: 31-72 years Sex: M+F Population Size: 66 Sources: |
|
200 mg 3 times / day multiple, oral Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy, 48 years n = 1 Health Status: unhealthy Condition: progressive shoulder pain Age Group: 48 years Sex: F Population Size: 1 Sources: |
Disc. AE: Bone marrow granuloma... AEs leading to discontinuation/dose reduction: Bone marrow granuloma (1 patient) Sources: |
100 mg 2 times / day multiple, oral Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: |
unhealthy, 64 years n = 1 Health Status: unhealthy Condition: rheumatoid arthritis Age Group: 64 years Sex: F Population Size: 1 Sources: |
Disc. AE: Thrombocytopenic purpura... AEs leading to discontinuation/dose reduction: Thrombocytopenic purpura (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bone marrow granuloma | 1 patient Disc. AE |
200 mg 3 times / day multiple, oral Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy, 48 years n = 1 Health Status: unhealthy Condition: progressive shoulder pain Age Group: 48 years Sex: F Population Size: 1 Sources: |
Thrombocytopenic purpura | 1 patient Disc. AE |
100 mg 2 times / day multiple, oral Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: |
unhealthy, 64 years n = 1 Health Status: unhealthy Condition: rheumatoid arthritis Age Group: 64 years Sex: F Population Size: 1 Sources: |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6616956
It was investigated the possibility of oxyphenbutazone (OPh) inhibited the complement system and thus ameliorated the acute pathological changes induced by immune complexes. Treatment of fresh human serum with OPh inhibited both the classical and alternative complement (C) pathway activities in a dose-dependent fashion with a 50% inhibition dose 1.3 mg/ml. OPh was shown to form complexes with C5, thereby inhibiting the interaction between C3b and C5 and the cleavage of the latter into phlogistic fragments.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:03:17 UTC 2023
by
admin
on
Sat Dec 16 10:03:17 UTC 2023
|
Record UNII |
86B165MRR5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
86B165MRR5
Created by
admin on Sat Dec 16 10:03:17 UTC 2023 , Edited by admin on Sat Dec 16 10:03:17 UTC 2023
|
PRIMARY | |||
|
57148-78-4
Created by
admin on Sat Dec 16 10:03:17 UTC 2023 , Edited by admin on Sat Dec 16 10:03:17 UTC 2023
|
PRIMARY | |||
|
SUB03593MIG
Created by
admin on Sat Dec 16 10:03:17 UTC 2023 , Edited by admin on Sat Dec 16 10:03:17 UTC 2023
|
PRIMARY | |||
|
100000085513
Created by
admin on Sat Dec 16 10:03:17 UTC 2023 , Edited by admin on Sat Dec 16 10:03:17 UTC 2023
|
PRIMARY | |||
|
72941570
Created by
admin on Sat Dec 16 10:03:17 UTC 2023 , Edited by admin on Sat Dec 16 10:03:17 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |